Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study
Authors' conclusion
ERA patients managed by a T2T strategy did not develop excess CVE compared with CV risk factor-matched controls over 5 years.
Study context
- Population
- Patients with RA from city-wide hospital data and the ERA registry, excluding those on antiplatelet/anticoagulant agents or with pre-existing CVD, CKD or other autoimmune diseases
- Comparison
- ERA patients managed by treat-to-target (T2T) vs cardiovascular (CV) risk factor-matched non-RA controls; HRA patients on routine care vs matched controls
- Outcome
- First occurrence of a CV event
- Follow-up
- Up to 5 years
Methodological detailsobservational, each ERA/HRA patient matched to three non-RA controls on age, gender and CV risk factors, city-wide hospital data and ERA registry, follow-up up to 5 years
- Observational
- Each ERA/HRA patient matched to three non-RA controls on age, gender and CV risk factors
- City-wide hospital data and ERA registry
- Follow-up up to 5 years
Main finding
As reported in the abstract
First CV event
Hazard ratio (95% CI)
ERAvs ERA controlssimilar incidence
0.53(0.15–1.79)
HRAvs HRA controls
1.9(1.16–3.13)
Observational data: associations, not effects.
Further findings
CV event incidence, ERA vs HRA
- Incidence significantly lower in ERA than HRA; difference insignificant after adjusting for inflammation, MTX use and traditional CV risk factors
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study. Rheumatology (Oxford). Published 27 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →